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The advances in low-grade lymphoma & T-cell lymphoma
from the 2008 ASH meeting were presented. These
included therapeutic regimens for low grade lymphoma,
frontline bendamustine plus rituximab data, radioimmu-
notherapy consolidation in advanced disease, idiotype
vaccine, and other novel therapeutic agents such as next
generation anti-CD20 GA101, syk inhibitor Fostamatinib
in treatment of low-grade lymphoma. In T-cell lym-
phoma, updates were discussed on phase II HOVON 69
trial data of combination of alemtuzumab/CHOP, prala-
trexate and romidepsin for relapsed/refractory PTCL, L-
asparaginase-containing regimen for extranodal NK/T-cell
lymphoma.
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